期刊文献+

RP-HPLC法测定降血压肽/聚乳酸-羟基乙酸微球中主药含量及包封率 被引量:2

Determination of Main Components in AHP/PLGA Microspheres by RP-HPLC and Its Encapsulation Efficiency
原文传递
导出
摘要 目的:建立测定降血压肽(AHP)/聚乳酸-羟基乙酸(PLGA)微球中AHP含量和包封率的反相高效液相色谱(RP-HPLC)法。方法:样品经二氯甲烷破坏并用水萃取后进行测定。反相色谱柱为Eclipse XDB-C18,流动相为乙腈-水(含0.05%三氟乙峰酸)均=得1到7∶很83好,流的速分为离1,.0A mHPL.检m测in浓-1,度柱线温性为范30围℃为,2检5~测6波25长μ为g.1m9L9-n(1mr,=进0样.99量9为9),2平0μ均L回。收结率果为:在9此8.7色8%谱,条日件内下和A日H间P与精辅密料度及分溶别为剂0.53%、0.86%(n=5)。结论:所建立的方法操作简单、快速,结果准确、可靠,可用于AHP/PLGA微球中主药含量及包封率的测定。 OBJECTIVE: To establish RP-HPLC method for the content determination of AHP and encapsulation efficacy detection in AHP/PLGA microsphere.METHODS: The microspheres were dissolved by methylene dichloride,and the drug encapsulated in the microspheres could be extracted by water.The separation was performed on Eclipse XDB-C18 column with mobile phase consisted of acetonitrile-water(0.05%TFA)(17 ∶ 83) at flow rate of 1.0 mL·min^-1.The detection wavelength was set at 199 nm and column temperature was 30 ℃.Injection volume was 20 μL.RESULTS: AHP was well-separated from other components.The linear range of AHP was 25~625 μg·mL^-1(r=0.999 9) with an average recovery of 98.78%.The RSD of intra-day and inter-day were 0.53% and 0.86%(n=5).CONCLUSION: The method is simple,rapid,accurate and reliable for the content determination and encapsulation efficacy detection of AHP/PLGA microspheres.
出处 《中国药房》 CAS CSCD 北大核心 2010年第29期2760-2762,共3页 China Pharmacy
基金 广东省科技计划项目(粤科规划字[2009]159号)
关键词 降血压肽 聚乳酸-羟基乙酸 微球 RP-HPLC法 含量 包封率 Antihypertensive peptide PLGA Microsphere RP-HPLC Content Encapsulation efficiency
  • 相关文献

参考文献6

二级参考文献19

  • 1Gao P,Ding P,Xu H,et al.In vitro and in vivo characterization of huperzine a loaded microspheres made from end-group uncapped poly(D,L-lactide acid) and poly(D,L-lactide-co-glycolide acid)[J].Chem Pharm Bull (Tokyo),2006,54(1):89-93.
  • 2Andrieu-Soler C,Aubert-Pouessel A,Doat M,et al.Intravitreous injection of PLGA microspheres encapsulating gdnf promotes the survival of photoreceptors in the rd1/rd1 mouse[J].Mol Vis,2005,11:1002-1011.
  • 3Gavini E,Chetoni P,Cossu M,et al.PLGA microspheres for the ocular delivery of a peptide drug,vancomycin using emulsification/spray-drying as the preparation method:in vitro/in vivo studies[J].Eur J Pharm Biopharm,2004,57(2):207-212.
  • 4Genentech patient information letter,June 2004.http://www.nutropin.com/patient/1 9 nutropin depot.jsp.
  • 5Zidan AS,Sammour OA,Hammad MA,et al.Formulation of anastrozole microparticles as biodegradable anticancer drug carriers[J].AAPS Pharm Sci Tech,2006,7(3):61.
  • 6Makino K,Nakajima T,Shikamura M,et al.Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres:effects of molecular weight and composition of PLGA on release of rifampicin[J].Colloids Surf B Biointerfaces,2004,36(1):35-42.
  • 7Tomoda K,Kojima S,Kajimoto M,et al.Effects of pulmonary surfactant system on rifampicin release from rifampicin-loaded PLGA microspheres[J].Colloids Surf B Biointerfaces,2005,45(1):1-6.
  • 8Armstrong DK,Fleming GF,Markman M,et al.A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (paclimer) in recurrent ovarian cancer:a gynecologic oncology group study[J].Gynecol Oncol,2006,103(2):391-396.
  • 9Gupte A,Ciftci K.Formulation and characterization of paclitaxel,5-fu and paclitaxel + 5-fu microspheres[J].Int J Pharm,2004,276(1-2):93-106.
  • 10Cheng J,Chi Q,Qie J,et al.Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist[J].Chem Pharm Bull (Tokyo),2006,54(9):1259-1265.

共引文献23

同被引文献25

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部